StockData

Novo Nordisk A S vs Dr Reddys Laboratories

NVO and RDY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NVO and RDY compare

Novo Nordisk A S grew revenue faster over the last twelve months (6.4% versus 3.2% for Dr Reddys Laboratories).

Dr Reddys Laboratories scores higher on the StockData Score (7 against 4 for Novo Nordisk A S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNVORDY
Size and price
Share price$40.00$14.17
Change, 1 year−22.1%5.7%
Change, 5 years−29.5%11.8%
Beta (5Y)0.760.37
Employees70K–
StockData Score
Total score47 (better)
Valuation score00
Growth score2 (better)1
Performance score02 (better)
Health score24 (better)
Dividend score00
Growth
Revenue growth (TTM)6.4% (better)3.2%
Revenue growth, 5Y average19.5% (better)12.1%
Net income growth (TTM)–−24.2%
EPS growth (TTM)1.8% (better)−24.1%
EPS growth, 5Y average20.7% (better)19.9%
Profitability
Gross margin81.0% (better)52.8%
Operating margin41.3% (better)15.0%
Net margin–12.8%
FCF margin19.1% (better)10.0%
Return on equity–12.1%
Return on invested capital–9.7%
Financial health
Debt / equity–0.21
Net debt / EBITDA0.82 (better)0.87
Interest coverage18.8× (better)13.5×
Current ratio0.801.80 (better)
Piotroski F-score–4
Dividends and buybacks
Payout ratio–15.5%
Years of dividend growth–0
Dividend growth, 5Y average–9.9%
Ownership
Held by institutions7.3%15.1%
Held by insiders0.00%13.6%
Superinvestors holding1–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.